Glanzmann's thrombasthenia causes: Difference between revisions
No edit summary |
m Bot: Removing from Primary care |
||
(7 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Glanzmann's thrombasthenia}} | {{Glanzmann's thrombasthenia}} | ||
{{CMG}}, {{AE}} {{OK}}, [[User:Niush.D|Niyousha Danesh, MD-MPH]] | |||
{{CMG}} | |||
==Overview== | ==Overview== | ||
Glanzmann's thrombasthenia can be inherited in an [[autosomal]] [[recessive]] manner or acquired as an [[autoimmune disorder]]. | Glanzmann's thrombasthenia can be inherited in an [[autosomal]] [[recessive]] manner or acquired as an [[autoimmune disorder]]. In the hereditary type of [[Glanzmann's thrombasthenia]] GPIIb/IIIa (ITG αIIbβ3) is qualitative or quantitative disorder. The [[autoantibodies]] production is the main cause of acquired [[Glanzmann's thrombasthenia]] It can be produced in the [[Acute lymphoblastic leukemia]], [[Non-Hodgkin lymphoma]], [[Multiple myeloma]], [[Hairy cell leukemia]], [[Myelodysplastic syndrome]], [[Idiopathic thrombocytopenic purpura|Immune thrombocytopenic purpura]] (ITP), [[Pregnancy]], [[Autoimmune disease|Autoimmune diseases]] (eg, [[systemic lupus erythematosus]], [[Immune]] [[thrombocytopenia]]),Anti-thrombotic drugs use , like [[abciximab]], [[eptifibatide]], and [[tirofiban]] which all antagonize αIIbβ3 and [[Platelet transfusions]]. | ||
In the hereditary type of | |||
==Causes== | ==Causes== | ||
In the hereditary type of Glanzmann's thrombasthenia GPIIb/IIIa (ITG αIIbβ3) is qualitative or quantitative | In the hereditary type of [[Glanzmann's thrombasthenia]] GPIIb/IIIa (ITG αIIbβ3) is qualitative or quantitative disorder. The [[autoantibodies]] production is the main cause of acquired [[Glanzmann's thrombasthenia]] It can be produced in the of following conditions:<ref name="pmid3055677">{{cite journal |vauthors=Bierling P, Fromont P, Elbez A, Duedari N, Kieffer N |title=Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient |journal=Vox Sang. |volume=55 |issue=2 |pages=109–13 |date=1988 |pmid=3055677 |doi= |url=}}</ref><ref name="pmid15720967">{{cite journal |vauthors=McMillan R |title=The role of antiplatelet autoantibody assays in the diagnosis of immune thrombocytopenic purpura |journal=Curr. Hematol. Rep. |volume=4 |issue=2 |pages=160–5 |date=March 2005 |pmid=15720967 |doi= |url=}}</ref><ref name="pmid15461628">{{cite journal |vauthors=Tholouli E, Hay CR, O'Gorman P, Makris M |title=Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder |journal=Br. J. Haematol. |volume=127 |issue=2 |pages=209–13 |date=October 2004 |pmid=15461628 |doi=10.1111/j.1365-2141.2004.05173.x |url=}}</ref> | ||
* [[Acute lymphoblastic leukemia]] | |||
The autoantibodies production is the main cause of acquired Glanzmann's thrombasthenia | * [[Non-Hodgkin lymphoma]] | ||
* [[Multiple myeloma]] | |||
* [[Hairy cell leukemia]] | |||
* [[Myelodysplastic syndrome]] | |||
* [[Idiopathic thrombocytopenic purpura|Immune thrombocytopenic purpura]] (ITP)<ref name="pmid9864781">{{cite journal |vauthors=Granel B, Swiader L, Veit V, Rey J, Reviron D, Disdier P, Harlé JR, Weiller PJ |title=[Pseudo-Glanzmann thrombasthenia in the course of autoimmune thrombocytopenic purpura] |language=French |journal=Rev Med Interne |volume=19 |issue=11 |pages=823–5 |date=November 1998 |pmid=9864781 |doi= |url=}}</ref> | |||
* [[Pregnancy]]<ref name="pmid2915873">{{cite journal |vauthors=Peaceman AM, Katz AR, Laville M |title=Bernard-Soulier syndrome complicating pregnancy: a case report |journal=Obstet Gynecol |volume=73 |issue=3 Pt 2 |pages=457–9 |date=March 1989 |pmid=2915873 |doi= |url=}}</ref> | |||
* [[Autoimmune disease|Autoimmune diseases]] (eg, [[systemic lupus erythematosus]], [[Immune]] [[thrombocytopenia]])<ref name="pmid24979837">{{cite journal| author=Blickstein D, Dardik R, Rosenthal E, Lahav J, Molad Y, Inbal A| title=Acquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies. | journal=Isr Med Assoc J | year= 2014 | volume= 16 | issue= 5 | pages= 307-10 | pmid=24979837 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24979837 }}</ref><ref name="pmid16610580">{{cite journal |vauthors=Yee NS, Schuster SJ |title=Clinical remission of acquired thrombasthenia with low-dose methotrexate in a patient with systemic lupus erythematosus |journal=Mayo Clin. Proc. |volume=81 |issue=4 |pages=566–7 |date=April 2006 |pmid=16610580 |doi=10.4065/81.4.566-a |url=}}</ref> | |||
* Drugs : Anti-thrombotic drugs use , like [[abciximab]], [[eptifibatide]], and [[tirofiban]] which all antagonize αIIbβ3<ref name="pmid1871709">{{cite journal |vauthors=Meyer M, Kirchmaier CM, Schirmer A, Spangenberg P, Ströhl C, Breddin K |title=Acquired disorder of platelet function associated with autoantibodies against membrane glycoprotein IIb-IIIa complex--1. Glycoprotein analysis |journal=Thromb. Haemost. |volume=65 |issue=5 |pages=491–6 |date=May 1991 |pmid=1871709 |doi= |url=}}</ref> | |||
* Autoimmune diseases, | * [[Platelet transfusions]]<ref name="pmid26185478">{{cite journal| author=Solh T, Botsford A, Solh M| title=Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. | journal=J Blood Med | year= 2015 | volume= 6 | issue= | pages= 219-27 | pmid=26185478 | doi=10.2147/JBM.S71319 | pmc=4501245 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26185478 }}</ref> | ||
* Drugs : | |||
* | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Line 31: | Line 23: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Latest revision as of 21:52, 29 July 2020
Glanzmann's thrombasthenia |
Differentiating Glanzmann's thrombasthenia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glanzmann's thrombasthenia causes On the Web |
American Roentgen Ray Society Images of Glanzmann's thrombasthenia causes |
Risk calculators and risk factors for Glanzmann's thrombasthenia causes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2], Niyousha Danesh, MD-MPH
Overview
Glanzmann's thrombasthenia can be inherited in an autosomal recessive manner or acquired as an autoimmune disorder. In the hereditary type of Glanzmann's thrombasthenia GPIIb/IIIa (ITG αIIbβ3) is qualitative or quantitative disorder. The autoantibodies production is the main cause of acquired Glanzmann's thrombasthenia It can be produced in the Acute lymphoblastic leukemia, Non-Hodgkin lymphoma, Multiple myeloma, Hairy cell leukemia, Myelodysplastic syndrome, Immune thrombocytopenic purpura (ITP), Pregnancy, Autoimmune diseases (eg, systemic lupus erythematosus, Immune thrombocytopenia),Anti-thrombotic drugs use , like abciximab, eptifibatide, and tirofiban which all antagonize αIIbβ3 and Platelet transfusions.
Causes
In the hereditary type of Glanzmann's thrombasthenia GPIIb/IIIa (ITG αIIbβ3) is qualitative or quantitative disorder. The autoantibodies production is the main cause of acquired Glanzmann's thrombasthenia It can be produced in the of following conditions:[1][2][3]
- Acute lymphoblastic leukemia
- Non-Hodgkin lymphoma
- Multiple myeloma
- Hairy cell leukemia
- Myelodysplastic syndrome
- Immune thrombocytopenic purpura (ITP)[4]
- Pregnancy[5]
- Autoimmune diseases (eg, systemic lupus erythematosus, Immune thrombocytopenia)[6][7]
- Drugs : Anti-thrombotic drugs use , like abciximab, eptifibatide, and tirofiban which all antagonize αIIbβ3[8]
- Platelet transfusions[9]
References
- ↑ Bierling P, Fromont P, Elbez A, Duedari N, Kieffer N (1988). "Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient". Vox Sang. 55 (2): 109–13. PMID 3055677.
- ↑ McMillan R (March 2005). "The role of antiplatelet autoantibody assays in the diagnosis of immune thrombocytopenic purpura". Curr. Hematol. Rep. 4 (2): 160–5. PMID 15720967.
- ↑ Tholouli E, Hay CR, O'Gorman P, Makris M (October 2004). "Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder". Br. J. Haematol. 127 (2): 209–13. doi:10.1111/j.1365-2141.2004.05173.x. PMID 15461628.
- ↑ Granel B, Swiader L, Veit V, Rey J, Reviron D, Disdier P, Harlé JR, Weiller PJ (November 1998). "[Pseudo-Glanzmann thrombasthenia in the course of autoimmune thrombocytopenic purpura]". Rev Med Interne (in French). 19 (11): 823–5. PMID 9864781.
- ↑ Peaceman AM, Katz AR, Laville M (March 1989). "Bernard-Soulier syndrome complicating pregnancy: a case report". Obstet Gynecol. 73 (3 Pt 2): 457–9. PMID 2915873.
- ↑ Blickstein D, Dardik R, Rosenthal E, Lahav J, Molad Y, Inbal A (2014). "Acquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies". Isr Med Assoc J. 16 (5): 307–10. PMID 24979837.
- ↑ Yee NS, Schuster SJ (April 2006). "Clinical remission of acquired thrombasthenia with low-dose methotrexate in a patient with systemic lupus erythematosus". Mayo Clin. Proc. 81 (4): 566–7. doi:10.4065/81.4.566-a. PMID 16610580.
- ↑ Meyer M, Kirchmaier CM, Schirmer A, Spangenberg P, Ströhl C, Breddin K (May 1991). "Acquired disorder of platelet function associated with autoantibodies against membrane glycoprotein IIb-IIIa complex--1. Glycoprotein analysis". Thromb. Haemost. 65 (5): 491–6. PMID 1871709.
- ↑ Solh T, Botsford A, Solh M (2015). "Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options". J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.